Dirk Huebner

4.0k citations

44 papers · 1.8k indexed · 1 hit paper · h-index 15

Impact in

Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment
Oncology top 2%
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research

Papers in

Pathology and Forensic Medicine 30
- Lymphoma Diagnosis and Treatment 30
Dermatology 10
- Cutaneous lymphoproliferative disorders research 10

Co-authors: Joseph M. Connors Michelle A. Fanale Naomi Hunder Emily K. Larsen Stephen M. Ansell Anas Younes Joseph D. Rosenblatt Robert Chen
Journals: Blood (18 papers)Journal of Clinical Oncology (6 papers)Biology of Blood and Marrow Transplantation (3 papers)British Journal of Haematology (2 papers)Current Medical Research and Opinion (2 papers)
Partner nations: United States United Kingdom Italy

In The Last Decade

Dirk Huebner

42 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial 2015 · 477 citations

Peers

Countries citing papers authored by Dirk Huebner

Since Specialization

Citations

This map shows the geographic impact of Dirk Huebner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Huebner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Huebner more than expected).

Fields of papers citing papers by Dirk Huebner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Huebner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Huebner. The network helps show where Dirk Huebner may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Dirk Huebner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Dirk Huebner Line = papers co-authored together Dirk Huebner links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A dose optimization phase 1b/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 x CD3 ADAPTIRÒ molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy Blood ·Justin M. Watts, Gautam Borthakur, Tara L. Lin, Nashat Gabrail, Kruti Patel, Yazan F. Madanat, Joshua F. Zeidner, Noor M. Khaskhely, Lynn Bonham, Michelle R. Nelson, Яна Сергеевна Житарь, MA Keqin, Sheriff Kandeh, A Majczak, Dirk Huebner, Michael B. Maris	2025	0
2	Five-Year Survival Results: Frontline Brentuximab Vedotin in Combination with CHP in Patients with CD30-Expressing Peripheral T-Cell Lymphomas Blood ·Michelle A. Fanale, Sarah McCue Horwitz, Andres Forero‐Torres, Nancy L. Bartlett, Ranjana H. Advani, Barbara Pro, Robert W. Chen, Andrew Davies, Tim Illidge, Jerold N. Chip, Dirk Huebner, Hong Ren, Andrei R. Shustov	2017	3
3	OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC) Journal of Thoracic Oncology ·Taofeek K. Owonikoko, Kristiaan Nackaerts, Tibor Csőszi, Gyula Ostoros, Christina S. Baik, Claudio Dansky Ullmann, Erin Zagadailov, Emily Sheldon‐Waniga, Dirk Huebner, E. Jane Leonard, David R. Spigel	2017	17
4	Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies Investigational New Drugs ·Xiaofei Zhou, John Nemunaitis, Shubham Pant, Todd M. Bauer, Manish R. Patel, John Sarantopoulos, A. Craig Lockhart, Daniel B. Goodman, Dirk Huebner, Diane R. Mould, Karthik Venkatakrishnan	2017	6
5	Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor EBioMedicine ·Huifeng Niu, Hyunjin Shin, Feng Gao, 琢磨齋藤, Brittany Bahamón, Hadi Danaee, Bohuslav Melichar, Sumaira Niaz, Robert L. Coleman, Gerald S. Falchook, Antoine Adenis, Kian Behbakht, Angela DeMichele, Elizabeth Claire Dees, Kimberly Perez, Ursula A. Matulonis, Piotr Sawrycki, Dirk Huebner, Jeffrey Ecsedy	2017	12
6	Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat Leukemia & lymphoma ·Ashish Gautam, Yanyan Zhu, Esprit Ma, Shih-Yuan Lee, Erin Zagadailov, Tomas Kandl, Akshara Richhariya, Vijayveer Bonthapally, Dirk Huebner	2017	2
7	Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas Critical Reviews in Oncology/Hematology ·Pier Luigi Zinzani, Vijayveer Bonthapally, Dirk Huebner, Richard A. Lutes, Andy Chi, Stefano Pileri	2016	34
8	Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse Biology of Blood and Marrow Transplantation ·John Sweetenham, Jan Walewski, Nikhil Arun Naik, Tamás Masszi, Edward Agura, Jerzy Hołowiecki, Muneer H. Abidi, Andy I. Chen, Pat Stiff, Simonetta Viviani, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanová, Anna Sureda, Dirk Huebner, Emily K. Larsen, Naomi Hunder, Craig H. Moskowitz	2016	12
9	Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas Critical Reviews in Oncology/Hematology ·Pier Luigi Zinzani, Vijayveer Bonthapally, Dirk Huebner, Richard A. Lutes, Andy Chi, Stefano Pileri	2016	25
10	Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet ·Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi, Edward Agura, Jerzy Hołowiecki, Muneer H. Abidi, Andy I. Chen, Patrick J. Stiff, Alessandro M. Gianni, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanová, John Sweetenham, Anna Sureda, Dirk Huebner, Eric L. Sievers, Andy Chi, Emily K. Larsen, Naomi Hunder, Jan Walewski Hit paper breakdown →	2015	477
11	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data Current Medical Research and Opinion ·Vijayveer Bonthapally, Eric Q. Wu, Alexander R. Macalalad, Hongbo Yang, Oluwatoyin Shonukan, Yi Liu, Andy Chi, Dirk Huebner	2015	12
12	Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis Current Medical Research and Opinion ·Vijayveer Bonthapally, Hongbo Yang, Rajeev Ayyagari, Emily Gotink, Adalberto Dantas de Medeiros, Eric Q. Wu, Ashish Gautam, Andy Chi, Dirk Huebner	2015	9
13	Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse Blood ·John Sweetenham, Jan Walewski, Auayporn Nademanee, Tamás Masszi, Edward Agura, Jerzy Hołowiecki, Muneer H. Abidi, Andy I. Chen, Patrick J. Stiff, Simonetta Viviani, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanová, Anna Sureda, Dirk Huebner, Emily K. Larsen, Naomi Hunder, Craig H. Moskowitz	2015	21
14	Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies Journal of Hematology & Oncology ·Nancy L. Bartlett, Robert Chen, Michelle A. Fanale, Pauline Brice, Ajay K. Gopal, Scott E. Smith, Ranjana H. Advani, Jeffrey Matous, Radhakrishnan Ramchandren, Joseph D. Rosenblatt, Dirk Huebner, Ramsha Jeoffrey, Laurie E. Grove, Andres Forero‐Torres	2014	136
15	The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma Blood ·Craig H. Moskowitz, Nikhil Arun Naik, Tamás Masszi, Edward Agura, Jerzy Hołowiecki, Muneer H. Abidi, Andy I. Chen, Patrick J. Stiff, Alessandro M. Gianni, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanová, John Sweetenham, Anna Sureda, Dirk Huebner, Emily K. Larsen, Naomi Hunder, Jan Walewski	2014	11
16	Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study. Journal of Clinical Oncology ·Stephen M. Ansell, Anas Younes, Joseph M. Connors, Andrea Gallamini, Won Seog Kim, Jonathan W. Friedberg, Tatyana Feldman, Graham P. Collins, Nancy L. Bartlett, Jingyuan Wang, Carol Natalia Magera, Jessica Sachs, Dirk Huebner, Naomi Hunder, John Radford	2014	6
17	Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study The Lancet Oncology ·Anas Younes, Joseph M. Connors, Steven I. Park, Michelle A. Fanale, Megan M. O’Meara, Naomi Hunder, Dirk Huebner, Stephen M. Ansell	2013	201
18	Phase I/II study of brentuximab vedotin in pediatric patients (pts) with relapsed or refractory (RR) Hodgkin lymphoma (HL) or systemic anaplastic large-cell lymphoma (sALCL): Interim phase (ph) I safety data. Journal of Clinical Oncology ·Kathleen Neville, Lia Gore, Christine Mauz‐Körholz, Angelo Rosolen, Judith Landman‐Parker, Joan Sánchez-de-Toledo, Auke Beishuizen, J P L N Sastry, Adedigbo A. Fasanmade, Jingyuan Wang, Dirk Huebner, Franco Locatelli	2013	7
19	Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL). Journal of Clinical Oncology ·Anas Younes, John Radford, Stephen M. Ansell, Andrea Gallamini, Won Seog Kim, Tatyana Feldman, Mehdi Hamadani, TH Que, Jingyuan Wang, Dirk Huebner, Joseph M. Connors	2013	2
20	Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia Leukemia & lymphoma ·David F. Claxton, Harry P. Erba, Stefan Faderl, Martha Arellano, Roger M. Lyons, Tibor Kovacsovics, Janice Gabrilove, Dirk Huebner, Pritesh J. Gandhi, Hagop M. Kantarjian, (unknown)	2011	10

About Dirk Huebner

Dirk Huebner is a scholar working on Pathology and Forensic Medicine, Dermatology, Oncology, Genetics and Hematology, having authored 44 papers that have together received 1.8k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (30 papers), Cutaneous lymphoproliferative disorders research (10 papers), Viral-associated cancers and disorders (9 papers), CAR-T cell therapy research (8 papers), Chronic Lymphocytic Leukemia Research (6 papers), Acute Myeloid Leukemia Research (5 papers), CNS Lymphoma Diagnosis and Treatment (5 papers) and Microtubule and mitosis dynamics (5 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.4k citations), Oncology (1.1k citations), Dermatology (324 citations), Neurology (499 citations) and Genetics (330 citations). Dirk Huebner has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Joseph M. Connors, Michelle A. Fanale, Naomi Hunder, Emily K. Larsen, Stephen M. Ansell, Anas Younes, Joseph D. Rosenblatt, Robert Chen, Andy Chi and Nancy L. Bartlett. Their work appears in journals such as Blood, Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation, British Journal of Haematology and Current Medical Research and Opinion.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact